New drug duo aims to save kidneys in aggressive urinary tract cancer
NCT ID NCT05912816
First seen Jan 10, 2026 · Last updated May 21, 2026 · Updated 19 times
Summary
This study tests whether two drugs, disitamab vedotin and tislelizumab, given before surgery can help control high-risk upper tract urothelial carcinoma while allowing surgeons to remove only the tumor and keep the kidney. About 20 participants will receive the drugs every 3 weeks, then undergo kidney-sparing surgery. The goal is to see if this approach prevents cancer from coming back or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UPPER URINARY TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ethics Committee of Shanghai Renji Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.